Mechanistically, RBM15 regulates downstream target ATP citrate lyase (ACLY) expression via m6A modification, which is recognized by IGF2BP2, thereby activating ACLY, driving lipid biosynthesis, and enhancing tumor malignancy (Cai et al., 2025). Here, ACLY is linked to neoplasm.